Advanced Biomed Inc. 8-K

What Happened

• Advanced Biomed Inc. announced it entered into and closed a Share Purchase Agreement on December 23, 2025, selling 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited to an unrelated buyer, Wei Ha Hui.
• The aggregate purchase price was US$23,000 (based on a company-commissioned valuation report). All intellectual property owned by the Hong Kong subsidiary — including IP held by its wholly owned subsidiary Shanghai Sglcell Biotech Co., Ltd. — was transferred to the buyer at closing. The transaction was unanimously approved by the company’s board of directors.
• The company issued a press release on December 30, 2025, announcing completion of the disposition.

Key Details

• Buyer: Wei Ha Hui (unrelated third party).
• Target sold: Advanced Biomed (HK) Limited (100% of issued and outstanding shares).
• Purchase price: US$23,000 (closing date December 23, 2025).
• Intellectual property: All IP of the Hong Kong subsidiary, including IP of Shanghai Sglcell Biotech Co., Ltd., transferred at closing.
• Disclosure: Share Purchase Agreement filed as Exhibit 2.1 (portions redacted); press release filed as Exhibit 99.1.

Why It Matters

• The company received a cash consideration of US$23,000 and removed the Hong Kong subsidiary and its associated IP from its assets. Investors should watch subsequent periodic filings for any reported impact on Advanced Biomed’s balance sheet, operations, or revenue sources.
• The transfer of IP may affect the company’s future business lines tied to that subsidiary. The Board approved the sale and the company provided a public press release, so this is a completed, disclosed transaction rather than a proposed deal.